open access

Vol 64, No 6 (2006)
Other
Published online: 2006-06-27
Submitted: 2012-12-28
Get Citation

Original article
Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy

Jan Sochman, Barbora Krizova
Kardiol Pol 2006;64(6):559-564.

open access

Vol 64, No 6 (2006)
Other
Published online: 2006-06-27
Submitted: 2012-12-28

Abstract

Background: Contrast-induced nephropathy is a relatively common complication occurring after various procedures requiringiodisze contrast agent injection, especially in patients with pre-existing renal failure. Aim: This pilot study was designed to assess the effects of a high intravenous dose of N-acetylcysteine (NAC) on plasma creatinine concentration. Methods: Twenty patients with pre-existing renal insufficiency were given NAC at a dose of 100 mg/kg. No contrast agent was given to 10 patients (Group A), whereas 10 patients received contrast at the time of coronary angiography (Group B). Changes in plasma creatinine were assessed at 3 hours and one day following NAC administration. Results: In Group B, NAC prevented creatinine increase: baseline levels were 210.98±77.33 µmol/L, 200.26±71.94 µmol/L (NS) after 3 hours, and 203.80±83.94 µmol/L 24 hours later (NS). The following was seen in Group A patients: 201.21±42.28 µmol/L, 190.31±42.74 µmol/L (p<0.01), and 170.08±45.53 µmol/L (p<0.01), respectively. Conclusion: The results of this study confirm the effectiveness of NAC in prevention of contrast agent-induced renal impairment. In addition, we demonstrated the beneficial effects of NAC on renal function in patients who were not exposed to contrast agent. This pilot study should provide the basis for more comprehensive research and, also, for safe clinical practice.

Abstract

Background: Contrast-induced nephropathy is a relatively common complication occurring after various procedures requiringiodisze contrast agent injection, especially in patients with pre-existing renal failure. Aim: This pilot study was designed to assess the effects of a high intravenous dose of N-acetylcysteine (NAC) on plasma creatinine concentration. Methods: Twenty patients with pre-existing renal insufficiency were given NAC at a dose of 100 mg/kg. No contrast agent was given to 10 patients (Group A), whereas 10 patients received contrast at the time of coronary angiography (Group B). Changes in plasma creatinine were assessed at 3 hours and one day following NAC administration. Results: In Group B, NAC prevented creatinine increase: baseline levels were 210.98±77.33 µmol/L, 200.26±71.94 µmol/L (NS) after 3 hours, and 203.80±83.94 µmol/L 24 hours later (NS). The following was seen in Group A patients: 201.21±42.28 µmol/L, 190.31±42.74 µmol/L (p<0.01), and 170.08±45.53 µmol/L (p<0.01), respectively. Conclusion: The results of this study confirm the effectiveness of NAC in prevention of contrast agent-induced renal impairment. In addition, we demonstrated the beneficial effects of NAC on renal function in patients who were not exposed to contrast agent. This pilot study should provide the basis for more comprehensive research and, also, for safe clinical practice.
Get Citation

Keywords

N-acetylcysteine; non-ionic contrast medium; nephropathy

About this article
Title

Original article
Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 64, No 6 (2006)

Pages

559-564

Published online

2006-06-27

Bibliographic record

Kardiol Pol 2006;64(6):559-564.

Keywords

N-acetylcysteine
non-ionic contrast medium
nephropathy

Authors

Jan Sochman
Barbora Krizova

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl